MedTrace Logo

Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310

NCT05702450 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2024-10-15

No results posted yet for this study

Summary

This is a single-center, randomized, open study to evaluate the pharmacokinetics, safety and immunogenicity CM310 in healthy subjects.

Conditions

  • Healthy

Interventions

BIOLOGICAL

CM310

CM310 Recombinant Humanized Monoclonal Antibody Injection

Sponsors & Collaborators

  • Keymed Biosciences Co.Ltd

    lead INDUSTRY

Principal Investigators

  • Jie Hou · Peking University Care Luzhong Hospital

  • Hong Wang · Peking University Care Luzhong Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-22
Primary Completion
2023-07-26
Completion
2023-07-26

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05702450 on ClinicalTrials.gov